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ABSTRACT 
Background 
Hypomineralized matrix is a factor determining bone mineral density. Increased 
perilacunar hypomineralized bone area is caused by reduced mineralization by 
osteocytes. The importance of vitamin D in the mineralization by osteocytes was 
investigated in hemodialysis patients who underwent total parathyroidectomy (PTX) 
with immediate autotransplantation of diffuse hyperplastic parathyroid tissue. No 
previous reports on this subject exist. 
Methods 
 The study was conducted in 19 patients with renal hyperparathyroidism treated with 
PTX. In 15 patients, the serum calcium levels were maintained by subsequent 
administration of alfacalcidol (2.0 μg/day), intravenous calcium gluconate, and oral 
calcium carbonate for four weeks after PTX (Group I). This was, followed in a subset of 
four patients in Group I by a reduced dose of 0.5 μg/day until one year following PTX; 
this was defined as Group II. In the remaining four patients, who were not in Group I, 
the serum calcium levels were maintained without subsequent administration of 
alfacalcidol (Group III). Transiliac bone biopsy specimens were obtained in all groups 
before and 3 or 4 weeks after PTX to evaluate the change of hypomineralized bone area. 
In addition, patients from Group II underwent a third bone biopsy one year following 
PTX. 
Results 
 A significant decrease of perilacunar hypomineralized bone area was observed 3 or 4 
weeks after PTX in all Group I and II patients. The area was increased again in the 
Group II patients one year following PTX. In Group III patients, an increase of 
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hypomineralized bone area was observed four weeks after PTX.  
Conclusion 
 The maintenance of a proper dose of vitamin D is necessary for mineralization by 
osteocytes, which is important to increase bone mineral density after PTX for renal 
hyperparathyroidism. 
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Introduction 
Accumulated evidence suggests that the osteocyte is a crucial determinant of bone 
strength. The osteocyte network spreads extensively over the skeleton controlling 
osteocytic perilacunar/canalicular turnover and regulating some functions of osteoclasts 
and osteoblasts. Figure 1 was taken from a hemodialysis (HD) patient with renal 
hyperparathyroidism in this study, but it is not a result of this study. This figure was 
adopted to show the relationships between osteocytes and both osteoclasts and 
osteoblasts in HD patients with renal hyperparathyroidism (Figure 1).
(1-3) 
However, 
there have been few clinical papers about the role of the osteocyte in patients with 
chronic kidney disease (CKD) (Figure 1).
(4-7) 
It is likely that bone fragility in CKD 
patients suffering from renal hyperparathyroidism increases
(8,9)
 as a result of increased 
hypomineralized bone area caused by impaired mineralization by osteocytes,
(10,11)
 
increased woven bone area,
(12,13)
 and the reduced cortical bone area caused by cortical 
thinning and increased cortical porosity.
(14,15)
 The long-term reduction of osteocyte 
number generally leads to increased fracture risk.
(16)
 
Parathyroidectomy is an important treatment option for hyperparathyroid bone disease 
caused by renal hyperparathyroidism
(17,18)
 because this procedure is completed in about 
one hour with little bleeding. However, whether mineralized bone area generally 
increases following parathyroidectomy has not been also clarified. It was reported that 
parathyroidectomy with or without subsequent Vit. D administration increases bone 
mineral and reduces fracture risk of dialysis patients,
(17,18)
 but the importance of 
subsequent administration of biologically active vitamin D after parathyroidectomy on 
mineralization on lacunar surfaces by osteocytes has not been well studied. Total 
parathyroidectomy (PTX) with immediate autotransplantation of 150 mg of diffuse 
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hyperplastic parathyroid tissue is really important in patients with severe renal 
hyperparathyroidism.
(7,19)
 Osteoblast surface (Ob.S/BS) increases 1 week after 
parathyroidectomy and low turnover osteomalacia with severe hypophosphatemia 
transiently develops 4 weeks after the surgery, thereafter, serum phosphorus level 
gradually increases. And bone mineral density (BMD) is significantly increased after 
parathyroidectomy as presented in the previous papers.
(7,18,19)
 Thus, mineralization by 
osteocytes is critical to increase BMD in CKD patients, and its importance has been 
demonstrated in both CKD patients and animal models without CKD.
(1-3,4,7) 
 
We have demonstrated increased osteocyte death and mineralization at the osteocytic 
perilacunar/canalicular surface after PTX.
(7)
 And the degree of mineralization at the 
osteocytic perilacunar/canalicular surface is greater than that at the mineralization front 
by osteoblasts after PTX with subsequent administration of 2.0 μg/day of alfacalcidol 
(1α-hydroxyvitamin D3; Chugai Pharma Co. Ltd., Tokyo, Japan).
(7)
 The existence of the 
parathyroid hormone receptor
(20)
 and the effects of biologically activated Vit. D on the 
vitamin D receptor
(21)
 expressed by the osteocyte may affect these changes. Moreover, 
the number of osteocytes is markedly greater than that of osteoblasts
(22)
 and there is 
significantly more surface area for molecular exchange associated with osteocyte 
lacunae and canaliculi (1200 m
2
) than that found in Haversian/Volkmann’s canals (3.2 
m
2
) or cancellous surfaces (9.0 m
2
) in the male skeleton.
(23) 
 
The importance of activated Vit. D for mineralization by osteocytes in CKD patients 
must be explored. In this study, the change of hypomineralized bone area was analyzed 
in HD patients with and without Vit. D supplementation after PTX to ascertain the 
importance of Vit. D in perilacunar/canalicular mineralization by osteocytes.
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Materials and Methods 
Study design 
Six females and 13 males with an average age of 58.4 ± 8.8 (39-71) years who were 
under maintenance by HD were enrolled in this study. They had been on HD for an 
average of 14.1 ± 7.3 (1-25) years. Because the sensitivity of bone tissue to parathyroid 
hormone (PTH) is reduced in patients with diabetes mellitus:,
(24,25) 
none of the patients 
in this clinical study suffered from diabetes mellitus. If the serum levels of intact PTH 
were > 1000 pg/mL or total alkaline phosphatase was > 360 U/L in the HD patients, the 
patients with renal hyperparathyroidism were treated with PTX. This was usually 
because the condition was refractory to conservative therapy with Vit. D sterols. We 
included all patients who received PTX between 1996 and 2010. No patients received 
cinacalcet hydrochloride (HCl) (Amgen Inc. Thousand Oaks, CA, USA, Kyowa Hakko 
Kirin, Tokyo, Japan) treatment before PTX (Table 1). 
The 19 patients with renal hyperparathyroidism were divided into the three groups. - 
Group I, consisted of patients (n = 15) who received subsequent administration of 2.0 
μg/day of alfacalcidol for 3-4 weeks after PTX. - Group II, consisted of a subset of 4 
patients from Group I who received subsequent administration of 2.0 μg/day of 
alfacalcidol for 4 weeks after PTX, but a reduced dose of alfacalcidol (0.5 μg/day) from 
4 weeks to one year following PTX. Group III, consisted of a separate group of patients 
(n = 4) did not receive alfacalcidol administration postoperatively due to Vit. D allergy 
or to avoid extraosseous ossification caused by high Vit. D levels after surgery.
(26)
 
Serum PTH levels must be increased to avoid long-term low turnover bone disease to 
avoid increased microcracks and soft tissue ossification after PTX.
(27,28) 
Ca containing 
drugs, including intravenous Ca gluconate and oral Ca carbonate were administered to 
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all Group I and II patients to maintain the proper serum Ca levels, but the four patients 
of Group III received only Ca gluconate and Ca carbonate after PTX to avoid severe 
hypocalcemia. Serum Ca levels were measured once a couple of days after PTX. The 
dose of Ca administered was 57.5 ± 17.1 g (22.5-73.6 g) to the fifteen Group I patients 
and 37.0 ± 13.5 g (24.3-55.4 g) to Group III patients during the first 4 weeks after PTX. 
Transiliac bone biopsy specimens were obtained from the left iliac crest before PTX and 
from the right iliac crest 3 weeks (n = 3) or 4 weeks (n = 12) after PTX in Group I and 
before and 4 weeks after surgery in Group III (n = 4). In addition, the four patients from 
Group II (a subset of Group I) underwent a third bone biopsy from the left iliac crest 1 
year after PTX. As a result, the four Group II patients received bone biopsies three 
times (pre-surgery, 3-4 weeks after PTX, and one year after PTX). The patients were 
included only after consent was obtained. 
 
Parathyroidectomy  
A total of 19 HD patients received PTX for renal hyperparathyroidism after failure or 
lack of Vit. D therapy, and four or five parathyroid glands were successfully removed 
under general anesthesia in the patients. After the surgery, 150 mg of diffuse 
hyperplastic parathyroid tissue was autotransplanted into the adipose tissue of the 
abdominal wall,
(7,19)
 to avoid complications caused by long-term low bone 
turnover.
(27-29)
 In these 19 patients, serum intact PTH levels were measured by an 
immunoradiometric assay (Allegro intact PTH, Nichols Institute Diagnostics, San Juan 
Capistrano, CA, USA) or an electrochemiluminescence immunoassay (Elecsys PTH, 
Roche Diagnostics, GmbH, Mannheim, Germany); intact PTH levels fell to 25 pg/mL 
or less one week after PTX. In one patient, three parathyroid glands were removed and 
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serum intact PTH fell from 1092 to 212 pg/mL one week later and further to 76 pg/mL 
4 weeks after PTX. In this patient, 50 mg of diffuse hyperplastic parathyroid tissue had 
been autotransplanted. Nodular hyperplastic parathyroid tissue was not autotransplanted 
as it is highly possible for recurrence of hyperparathyroidism to occur after PTX.
(30)
 All 
patients resumed walking two days after PTX, because mechanical loading is important 
to maintain bone properties.
(31-33)
 These patients were treated with PTX with immediate 
autotransplantation between 1996 and 2010. 
 
Serum bone metabolism parameters  
The serum levels of intact PTH, tartrate-resistant acid phosphatase (TRACP; Means of 
colorimetry, using ρ-nitrophenyl phosphate as the substrate), deoxypyridinoline (DPD; 
High-performance liquid chromatography), carboxy-terminal propeptide of human type 
I procollagen (PICP; Radioimmunoassay kit (PICP ORION; Orion Diagnostica, Espoo, 
Finland)), and total alkaline phosphatase (total-ALP; Means of colorimetry, using 
ρ-nitrophenyl phosphate as the substrate) were measured before and 3.8 ± 0.4 (3 or 4) 
weeks after PTX in Groups I and II, and before and 4 weeks after PTX in Group III, 
although serum bone metabolism parameters are not sometimes reliable in HD 
patients.
(34)
 Serum intact PTH, calcium (Ca) and phosphorus (P) levels were measured 
and compared between 4 weeks and 1 year after PTX in Group II (Table 2). Blood 
samples were collected immediately before PTX and immediately before the iliac bone 
biopsies performed 4 weeks after PTX. Plasma 1.25(OH)2D3 (Immuno Diagnostic 
Systems Ltd, Boldon, UK radioimmunoassay kit) levels were measured in Group III 
patients, but not in Groups I or II.
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Bone histomorphometry  
Tetracycline hydrochloride (Japan Lederle, Tokyo, Japan) was administered for 2 or 3 
days with an inter-label period of 8 to 13 days. A 3-4 day washout period was allowed 
before the biopsy was taken in the patients. Static and dynamic histomorphometric 
parameters defined by Dempster et al. and Recker et al. were measured in the central 
portion of cancellous bone.
(35,36)
 In addition, the hypomineralized bone area normalized 
to total bone area (hypomineralized bone area; HM.B.Ar/B.Ar; %)
(10,11)
 was measured at 
the central portion of the cancellous bone by fluorescent light microscopy.  
Osteoclast surface (Oc.S/BS), eroded surface (ES/BS), osteoblast surface (Ob.S/BS) and 
osteoid surface (OS/BS) were measured in cancellous bone and statistically compared 
before and after PTX in all groups, and also 4 weeks and 1 year after PTX in Group II. 
Bone formation rate normalized to bone surface (BFR/BS; mm3/mm2/year) was 
measured 3-4 weeks after PTX in Groups I and III. However, BFR/BS was not 
measured one year after PTX in Group II. Hypomineralized bone area was measured in 
cancellous bone to compare the values obtained before and 3-4 weeks after PTX in all 
groups, and 4 weeks and 1 year after PTX in Group II. 
 
Raman spectroscopy  
Embedded biopsies were sanded to create a flat surface and then polished with a 3 μm 
diamond suspension followed by a 50 nm alumina suspension. We did Raman 
measurements from the same sections as those used form histology, but were not able to 
specifically target hypomineralized areas for measurement. Bone near edges was likely 
more plasticized than tissue in more centrally located regions, so all measures were 
targeted toward bone away from edges. However, given the current laser setup on the 
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Raman scope, we were not able to visualize any labels. Bone samples from nine patients 
were chosen for the Raman spectroscopy because these were the only patients for whom 
we could get informed consent to perform another analysis. Also, several patients had 
died before we were able to ask their permission for this analysis. Raman spectroscopy 
was performed using an InVia Raman Spectrometer (Renishaw, Wotton-under-Edge, 
United Kingdom). A 785 nm laser was focused on the bone surface using a 50X 
objective to a spot size of  1.3 μm. Eight sites within the trabecular regions were 
imaged ∼1 mm apart. Spectra were acquired following a 12s exposure and were 
averaged across 12 accumulations. Baseline correction was accomplished using 
Renishaw WiRE software intelligent fitting. Gaussian peaks were fit to the PO4
3
-ν1 
peak, and CO3
2
-ν1, peaks by second derivative spectroscopy in GRAMS/AI (Thermo 
Fisher Scientific, Waltham, MA). The extent of matrix mineralization was determined 
by the mineral/matrix ratio, calculated as the integrated area ratio of PO4
3
-ν1/Amide I. 
Mineral maturity/crystallinity was calculated as the inverse of the full width at half 
height of the PO4
3
-ν1 Gaussian peak. Type B carbonate substitution was calculated as 
the Gaussian peak area ratio of PO4
3
-ν1/CO3
2
-ν1. The 8 spectra acquired for each 
sample were averaged, yielding a single value for each Raman parameter to be used for 
analysis.
(37)
 
Informed consent was obtained from all patients after they were provided with a 
detailed explanation of both the risks and possible outcomes of bone biopsies and PTX.   
The procedure was conducted in accordance with the Declaration of Helsinki, and the 
study protocol was approved by the Institutional Review Board of Towa Hospital and 
its affiliated hospitals. The Institutional Review Board of Towa Hospital and its 
affiliated hospitals approved the study protocol. 
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Statistical Analysis  
Statistical analyses were conducted using JMP 13 (SAS Institute Inc., North Carolina, 
USA). The parameters pertaining to serum bone metabolism, histomorphometric 
parameters of bone turnover and hypomineralized bone area, and parameters obtained 
by Raman spectroscopy were compared with each other using nonparametric tests 
(Mann Whitney tests) or unpaired Student’s t tests. The parameters obtained by Raman 
spectroscopy were also compared before and after PTX using the Mann-Whitney test. 
Power analysis was computed with JMP post hoc using calculated means, standard 
deviations and sample size for each group and variable, and presented in Tables 2-5. 
 
Results 
Serum bone metabolism parameters  
Serum resorption parameters, including TRACP and DPD levels decreased and serum 
formation parameters, including PICP and total-ALP levels significantly increased after 
PTX in Group I (Table 2 (1)). Serum resorption parameters decreased and serum 
formation parameters increased in the four patients in Group III (Table 2 (3)), but 
neither of these differences was significant. Serum Ca levels remained unchanged, 
probably because they were maintained by intravenous Ca gluconate and oral Ca 
carbonate administration after PTX. Serum P levels significantly decreased after PTX in 
both Groups I and III (Tables 2 (1) and (3)). Plasma 1.25(OH)2D3 levels were extremely 
low in Group III patients (5.3 ± 2.2 (2.8-7.9) pg/mL); the normal range of plasma 
1.25(OH)2D3 level is from 20 to 60 pg/mL.  
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Histomorphometry of bone turnover  
Resorption parameters decreased after PTX in Group I (Table 3 (1)). Although 
Ob.S/BS was not significantly different before and after PTX (p = 0.083), OS/BS 
increased in Group I, possibly because of hypophosphatemia and a failure to mineralize 
newly deposited matrix (Table 3 (1)). In Group II, Oc.S/BS increased from 0 to 0.1 % 
one year after PTX (Table 3 (2)), probably because serum intact PTH increased by 
three-fold one year after surgery (Table 2 (2)). Bone resorption parameters (Oc.S/BS 
and ES/BS) decreased in all four patients after PTX in Group III, although the changes 
were not statistically significant (Table 3 (3)), probably because of the small sample size. 
BFR/BS was 0.020 ± 0.015 (0.003-0.032) mm
3
/mm
2
/year in Group I (Table 3 (1)) and 
was 0.026 ± 0.033 (0-0.070) mm
3
/mm
2
/year in Group III (Table 3 (3)) 4 weeks after 
PTX, but there was no statistical difference between these two groups even though 
Ob.S/BS was significantly greater in Group III than in Group I after PTX (Table 4). 
   
Histomorphometry of hypomineralized bone area  
HM.B.Ar/B.Ar significantly decreased from 17.3 ± 12.8 to 2.6 ± 3.2 % (p 0.001) after 
PTX in the Group I patients (Table 3 (1), Figures 2, 3a and 3b). These parameters were 
also compared between 4 weeks and 1 year after PTX in the four patients who 
underwent a third biopsy (Group II) after the dose of alfacalcidol was reduced from 2.0 
to 0.5 μg/day at 4 weeks. HM.B.Ar/B.Ar increased in all four patients (2.5 ± 1.8 vs. 
14.4 ± 5.0 %, p = 0.125) one year after PTX (Table 3 (2), Figure 2). In Group III, who 
did not receive alfacalcidol after PTX, HM.B.Ar/B.Ar increased in all four patients (6.0 
± 4.0 vs. 14.3 ± 3.5 %, p = 0.125) (Table 3 (3), Figures 4a, 4b and 4c). HM.B.Ar/B.Ar 
was significantly greater in Group I than in Group III after PTX (Table 4). 
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Raman spectroscopy for mineral matrix ratio, mineral maturity and crystallinity 
 The mineral-matrix ratio, shown as PO4
3
-ν1/Amide I, did not change following PTX 
surgery in Group I (n = 6; 2.317 ± 0.346 before PTX and 2.346 ± 0.333 after surgery) 
(Figure 5(1) and Table 5 (1)). Although the mineral-matrix ratio increased in all three 
patients after surgery in Group III (2.266 ± 0.172 vs. 2.646 ± 0.288) (Figure 5(1)), the 
change in this parameter was not significant (Table 5 (2)). Mineral maturity, defined by 
the bone’s carbonate content and shown as CO3
2
-ν1/PO4
3
-ν1, did not change following 
PTX surgery in Group I (n = 6; 0.222 ± 0.019 before PTX and 0.232 ± 0.027 after 
surgery) (Figure 5(2), Table 5 (1)). Although mineral maturity decreased from 0.259 to 
0.196 and 0.254 to 0.209 in two of three patients in Group III, the difference was not 
significant (0.255 ± 0.019 vs. 0.222 ± 0.034) (Figure 5(2), Table 5 (2)). Crystallinity of 
the mineral is shown in Figure 5(3). Crystallinity did not change post-PTX surgery in 
either Group I or Group III (Figure 5(3), Tables 5 (1) and (2)). However, crystallinity is 
not expected to change within 3-4 weeks after PTX. 
 
Discussion  
Development of low turnover osteomalacia following PTX is generally observed in 
patients with renal hyperparathyroidism.
(7,19,29,34)
 We previously demonstrated that 
mineralization around the osteocyte cell bodies and canaliculi was greater than that at 
the mineralization front after PTX followed by 2.0 μg/day of alfacalcidol 
administration.
(7)
 This finding is highly relevant and important as one of the causes of 
hypocalcemia and hypophosphatemia, namely, hungry bone syndrome after PTX in 
Group I.
(7)
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Matrix mineralization by osteocytes may be disturbed by various factors, including Vit. 
D deficiency
(11) 
and hypophosphatemia.
(38)
 In this study of patients with renal 
hyperparathyroidism, hypomineralized matrix was found in large bone areas probably 
because of a severe mineralization deficiency (Figure 2 (left photo)).
(10,11)  Following 
PTX, the hypomineralized bone matrix around osteocytes was reduced within four 
weeks by administration of 2.0 μg/day of alfacalcidol administration. However, when 
the dose was reduced to 0.5 μg/day of alfacalcidol four weeks after PTX to avoid 
long-term consequences of low turnover bone disease with hypoparathyroidism, the 
area of hypomineralized bone increased by 6-fold over the course of the following year 
(Group II). When no alfacalcidol was administered after PTX (Group III), the area of 
hypomineralized bone doubled within 4 weeks following PTX. The higher dose of 
biologically active Vit. D clearly suppresses the function of parathyroid tissue,
(12,13) 
but 
the lower dose of Vit. D or absence of Vit. D after PTX leads to increased 
hypomineralized bone area (Figures 4a, 4b and 4c). It is also possible that osteoid 
formation on the osteocyte lacunar walls continued after PTX, contributing to the 
increased hypomineralized bone matrix. The Vit. D receptor is expressed on 
osteocytes,
(21)
 and biologically active Vit. D may stimulate the receptor on the osteocyte, 
leading to increased matrix mineralization.  
These results indicate that Vit. D is required at least in moderate doses for adequate 
mineralization by osteocytes (Tables 3 and 4, Figures 2, 3 and 4). As a future study, 
whether the Vit. D sterols, including paricalcitol (19-nor-1α.25-dihydroxyvitamin D2) 
(AbbVie Inc. North Chicago, Illinois, USA) activate mineralization by osteocytes or not 
should be investigated.  
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Raman spectroscopy was used to further characterize changes in the perilacunar matrix 
around osteocytes. Raman spectroscopy showed that, mineralized matrix did not change 
significantly in patients whether they received alfacalcidol or not after PTX. 
Crystallinity of the deposited mineral did not change either, but this was an expected 
result only 3-4 weeks after PTX. This analysis showed that, mineralized matrix did not 
change significantly in patients whether they received alfacalcidol or not after PTX. 
Crystallinity of the deposited mineral did not change either, but this was an expected 
result only 3-4 weeks after PTX. 
The biopsies used here were embedded in plastic prior to Raman imaging. When 
sanding and polishing a surface for Raman, the plastic surface is flattened which then 
exposes some of the bone’s surface. In practice, patches of bone were exposed on a 
given surface, and even a small amount of surface plastic overlaying a section of bone 
will distort the Raman spectrum. In addition, given that the bone was embedded, bone 
near any surface, including near any osteocyte lacunae, would be plasticized which can 
alter this type of characterization. 
The second limitation of the study is that the post-year one bone biopsy was performed 
only in patients of group II. The additional limitation of the analysis is that the 
subsample was small, and we could not get permission for all of the patients in the study 
to perform this analysis. 
Based on these results, we suggest that that PTX followed by 2.0 μg/day of 
alfacalcidol administration is an important option to increase BMD in HD patients with 
hyperparathyroid bone disease caused by renal hyperparathyroidism. Biologically active 
Vit. D may be required at least in moderate doses for adequate mineralization by 
osteocytes to reduce hypomineralized bone area. However, a larger study is needed to 
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demonstrate this conclusively. Further study of osteocyte specific histological 
parameters and perilacunar changes in response to PTX and Vit. D administration in 
patients with renal hyperparathyroidism could further elucidate the role that osteocytes 
play in regulating bone matrix mineralization. 
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Figure legends;  
Figure 1- Osteoclasts, osteoblasts and osteocytes in patients with renal 
hyperparathyroidism 
The relationships between osteocytes and both osteoclasts and osteoblasts in patients 
with renal hyperparathyroidism is shown. 
Figure 2- Hypomineralized bone area before and after PTX in Group I 
Hypomineralized bone area was observed in a HD patient suffering from renal 
hyperparathyroidism (left photo). Reduction of hypomineralized bone area was 
observed 4 weeks after total parathyroidectomy (PTX) with immediate 
autotransplantation of the diffuse hyperplastic parathyroid tissue followed by 2.0 μg/day 
of alfacalcidol administration in a Group I patient. Mineralization within bone matrix 
presumably mediated by the osteocytic perilacunar/canalicular system was observed 4 
weeks after PTX. Mineralization within the matrix was activated by alfacalcidol 
administration (central photo). The single labelings caused by osteoblasts were also 
shown (central photo). Thereafter, hypomineralized bone area was increased again one 
year after PTX after reduction of alfacalcidol from 2.0 to 0.5 μg/day (right photo) 
(Group II). The lower dose of alfacalcidol is insufficient to maintain normal 
mineralization by osteocytes. 
Figure 3a- Osteocyte canaliculi after PTX in Group I (upper panels)  
The osteocyte canaliculi stained by tetracycline hydrochloride were clearly visible in a 
Group I patient after PTX followed by 2.0 μg/day of alfacalcidol administration. It is 
likely that mineralization within bone matrix presumably mediated by the osteocytic 
perilacunar/canalicular system was maintained if the HD patients receive 2.0 μg/day of 
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alfacalcidol after PTX. White arrows are pointing to osteocyte canaliculi stained by 
tetracycline hydrochloride. 
Figure 3b- Osteocyte canaliculi after PTX in Group I (lower panels)  
Osteocyte lacunae are shown and those on the right are stained by tetracycline 
hydrochloride. White arrows are pointing to osteocyte lacunar walls stained by 
tetracycline hydrochloride. 
Figure 4a- Hypomineralized bone area before and after PTX in Group III (upper 
panels)  
Increased hypomineralized bone area 4 weeks after PTX was found in a Group III 
patient not receiving alfacalcidol administration. The schema on the right shows both 
the single labelings caused by osteoblasts and hypomineralized bone area caused by 
osteocytes. These results indicate that vitamin D is required at least in moderate doses 
for adequate mineralization by osteocytes and osteoblasts. Mineralization in the 
osteocytic perilacunar/canalicular system was not observed around the osteocyte 
lacunae in a patient not receiving alfacalcidol. White arrows are pointing to (1) 
mineralized matrix by osteoblasts and (2) hypomineralized matrix caused by lack of 
mineralization by osteocytes.  
Figures 4b and 4c- Higher resolution images of osteocyte lacunae (middle panels 
(4b) and lower panels (4c))  
Higher resolution images of osteocyte lacunae within the hypomineralized bone area, as 
well as osteoblasts on top of the surface of the respective area were shown. White 
arrows are pointing to hypomineralized matrix area. 
Figure 5(1)- PO4
3
-ν1/Amide I values before and after PTX in Groups I and III  
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Mineral-matrix ratio is evaluated and shown as PO4
3
-ν1/Amide I. The mineral-matrix 
ratio did not change following PTX surgery in Group I. However, although the 
mineral-matrix ratio increased in all three patients after surgery in Group III, the change 
in this parameter was not significant probably due to the limitation of statistical power 
in this group (Tables 5 (1) and (2)). 
Figure 5(2)- CO3
2
-ν1/PO4
3
-ν1 values before and after PTX in Groups I and III  
The maturity of mineral deposited to matrix, defined by its carbonate content, was 
evaluated and is presented as CO3
2
-ν1/PO4
3
-ν1 (Figure 5(2)). Mineral maturity did not 
change following PTX surgery in Group I. Although mineral maturity decreased from 
0.259 to 0.196 and 0.254 to 0.209 in two patients of three patients after PTX in Group 
III, the difference was not significant. 
Figure 5(3)- Crystallinity/maturity values before and after PTX in Groups I and 
III  
Crystallinity did not change after PTX in either Group I or Group III. However, 
crystallinity is not expected to change within 3-4 weeks after PTX. 
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